Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Novartis Stories

2014-02-24 08:28:29

- FDA granted special use of Bexsero for nearly 20,000 UCSB students and staff in response to outbreak; the vaccine is licensed in Europe, Australia and Canada CAMBRIDGE, Mass., Feb. 24, 2014 /PRNewswire/ -- Novartis announced today that its meningococcal serogroup B (MenB) vaccine, Bexsero(®) (Meningococcal Group B Vaccine [rDNA, component, adsorbed]), will be used as part of a vaccination program at the University of California Santa Barbara (UCSB) that began today and will end on March 7....

2014-02-20 12:23:17

- Agrisure Duracade(TM) introductory launch program "Right to Grow" offers farmers step-change in corn rootworm control and 2014 grain marketing options MINNETONKA, Minn., Feb. 20, 2014 /PRNewswire/ -- Syngenta announced today an agreement with Gavilon Grain, LLC that provides grain marketing opportunities for farmers who choose to plant Agrisure Duracade, the cutting-edge corn rootworm (CRW) control technology that has been approved in the U.S. For farmers participating in the...

2014-02-19 16:21:15

DUBLIN, Feb. 19, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/frs7k2/animalveterinary ) has announced the addition of the "Concise Analysis of the International Animal/Veterinary Vaccines Market - Global Forecast to 2018" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The animal vaccines market studied is segmented by products, animal diseases, and technologies that are involved in developing vaccines for...

2014-02-17 23:02:57

ChinaMarketResearchReports.com adds Latest Report on “Investigation Report on China Valsartan Market, 2009-2018” to its store. Dallas, TX (PRWEB) February 17, 2014 Valsartan (Angiotan or Diovan) is an angiotensin II receptor antagonist (more commonly called an ARB, or angiotensin receptor blocker), with particularly high affinity for the type I (AT1) angiotensin receptor. In December 1996, Valsartan was approved by FDA. In the US, UK and Australia, valsartan is marketed by Novartis...

2014-02-17 08:24:51

BOSTON, Feb. 17, 2014 /PRNewswire/ -- MPM Capital and Atlas Venture announced today that portfolio company CoStim Pharmaceuticals, Inc. ("CoStim") has been acquired by Novartis for an undisclosed amount. CoStim, founded in 2012 by MPM Managing Director Luke Evnin together with MPM Managing Director-Operations Robert Millman, is an emerging immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer. "I am thrilled that...

2014-02-14 00:20:57

BASEL, Switzerland, Feb. 14, 2014 /PRNewswire/ -- Syngenta announced that the 2013 Annual Report on Form 20-F has been filed with the U.S. Securities and Exchange Commission. The document is available on the Syngenta website at www.syngenta.com; hard copies of the audited financial statements are available to shareholders free of charge upon request. Syngenta is one of the world's leading companies with more than 28,000 employees in over 90 countries dedicated to our purpose:...

2014-02-13 08:30:01

GAITHERSBURG, Md., Feb. 13, 2014 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today announced that the company has achieved the third milestone in its collaboration with Novartis for the development of treatments for hearing and balance disorders. In January 2014, Novartis filed an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) for the clinical development of CGF166, the lead product candidate under the collaboration. The IND was deemed...

2014-02-12 12:30:26

LONDON, Feb. 12, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Brazilian Pharmaceutical Market 2014-2024Report DetailsDrug selling in Brazil - this new analysis shows you trends, opportunities, and revenuesDo you want to assess the future of pharmaceuticals in Brazil? See what lies ahead, then. Visiongain's new report gives you revenue predictions, helping your work. There you discover financial results, trends, opportunities, and sales forecasts.So...

2014-02-06 23:02:16

The Catalent Applied Drug Delivery Institute today announced that it will hold its second European educational and training event, “Overcoming Bioavailability Challenges” at the Novartis global headquarters campus in Basel, Switzerland, on Thursday, March 27th. Somerset, NJ (PRWEB) February 06, 2014 The Catalent Applied Drug Delivery Institute today announced that it will hold its second European educational and training event, “Overcoming Bioavailability Challenges” at the...

2014-02-05 20:24:13

DUBLIN, February 5, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/rm8xc9/veterinary_health) has announced the addition of the "Concise Analysis of the International Veterinary Health Markets" [http://www.researchandmarkets.com/research/rm8xc9/veterinary_health ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Veterinary health products, including veterinary pharmaceuticals, biologicals...